This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

FORMA/BI Program

FORMA Therapeutics

Drug Names(s): FORMA/BI Program

Description: FORMA and Boehringer Ingelheim's novel collaboration program will develop small molecule drugs against oncology-relevant protein-protein interaction (PPI) targets.

Deal Structure: FORMA and Boehringer Ingelheim
In January 2012, FORMA and Boehringer Ingelheim signed a research and development collaboration deal to discover small molecule drugs against oncology-relevant protein-protein interaction (PPI) targets.

Partners: Boehringer Ingelheim GmbH


FORMA/BI Program News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug